Emergent BioSolutions receives Singapore regulatory approval for ACAM2000

Emergent BioSolutions (EBS) announced that Singapore’s Health Sciences Authority has approved an expanded indication for ACAM2000 to include prevention of mpox disease in adults determined to be at high risk for mpox infection. “The Singapore HSA approval of ACAM2000 for immunization against mpox in high-risk individuals demonstrates the strength and breadth of Emergent’s medical countermeasures portfolio,” said Simon Lowry, chief medical officer of Emergent. “We are committed to working with international regulatory authorities as part of our broader vision to become the leader in delivering protective and life-saving solutions to communities around the world.”